Protagonist Therapeutics Inc Share Price Nasdaq
Stocks
US74366E1029
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - PTS | - |
|
| Market Cap | 9.06B 0 7.92B 7.31B 6.74B 12.7B 873B 12.98B 87.35B 34.36B 427B 34.03B 33.29B 1,471B | P/E 2026 * |
35.7x | P/E 2027 * | -123x |
|---|---|---|---|---|---|
| Enterprise Value | 8.49B 0 7.42B 6.84B 6.31B 11.89B 817B 12.16B 81.81B 32.18B 400B 31.88B 31.18B 1,378B | EV / Sales 2026 * |
16.6x | EV / Sales 2027 * | 52.2x |
| Free-Float |
97.28% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Protagonist Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
CEO | Chief Executive Officer | 69 | 30/11/2008 |
Asif Ali
DFI | Director of Finance/CFO | 52 | 17/04/2022 |
Venkat Thalladi
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
BRD | Director/Board Member | 69 | 30/11/2008 |
Harold Selick
CHM | Chairman | 71 | 18/03/2014 |
William Waddill
BRD | Director/Board Member | 69 | 30/06/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.29% | -3.11% | -0.35% | +3.09% | 49.18B | |
| +3.90% | -0.39% | +386.06% | +593.85% | 39.58B | |
| -1.70% | +4.46% | +5.93% | +60.25% | 34.69B | |
| -2.01% | -0.76% | +28.41% | -8.01% | 34.42B | |
| +0.06% | +0.34% | +2.38% | +34.38% | 27.11B | |
| +0.46% | -3.49% | - | - | 16.21B | |
| -0.04% | -0.09% | +72.42% | +115.55% | 15.36B | |
| +1.12% | +1.91% | +14.54% | +19.16% | 14.05B | |
| 0.00% | +1.36% | +18.43% | -30.79% | 13.02B | |
| Average | +0.06% | +0.03% | +65.98% | +98.43% | 27.07B | |
| Weighted average by Cap. | -0.05% | -0.18% | +79.44% | +123.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 512M 0 447M 413M 380M 717M 49.27B 733M 4.93B 1.94B 24.13B 1.92B 1.88B 83.07B | 163M 0 142M 131M 121M 228M 15.67B 233M 1.57B 617M 7.67B 611M 598M 26.42B |
| Net income | 249M 0 217M 200M 185M 348M 23.94B 356M 2.4B 942M 11.72B 933M 913M 40.36B | -82.92M -0 -72.46M -66.87M -61.63M -116M -7.99B -119M -799M -314M -3.91B -311M -305M -13.46B |
| Net Debt | -574M -0 -502M -463M -427M -804M -55.27B -822M -5.53B -2.18B -27.07B -2.16B -2.11B -93.18B | -565M -0 -494M -455M -420M -791M -54.38B -809M -5.44B -2.14B -26.64B -2.12B -2.07B -91.69B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
